Shuttle Pharmaceuticals Holdings, Inc. issued 3,737,482 shares of common stock upon the conversion of Series B-1 and Series B-2 Preferred Stock as of September 14, 2026, subject to beneficial ownership limitations. Concurrently, the company issued warrants for approximately 927,114 shares at an exercise price of $10.30 per share and pre-funded warrants for approximately 16,932,508 shares following stockholder approval on September 9, 2026. These unregistered securities were issued in reliance on Section 4(a)(2) exemptions. Shuttle Pharmaceuticals Holdings, Inc. operates in the biopharmaceutical industry, focusing on drug discovery and development.

Shuttle Pharmaceuticals Holdings, Inc. entered into a First Amendment to its Merger Agreement with United Dogecoin Inc., reducing the 'Milestone Event' threshold for Mining Rigs from 2,000 to 500. The company is seeking parallel amendments to its Securities Purchase Agreement and Asset Purchase Agreement to align these definitions. This adjustment modifies the conditions for issuing pre-funded warrants or shares but does not change the maximum number of securities issuable upon satisfying the milestone. Shuttle Pharmaceuticals Holdings, Inc. operates in the pharmaceutical industry.

Shuttle Pharmaceuticals Holdings, Inc. received a notification from Nasdaq on August 28, 2026, indicating noncompliance with Listing Rule 5250(c)(1) due to the delayed filing of its Form 10-Q for the period ended June 30, 2026. The company has until October 27, 2026, to submit a compliance plan and may receive an extension until February 22, 2027, if accepted. Failure to regain compliance could result in delisting from Nasdaq. Shuttle Pharmaceuticals Holdings, Inc. operates in the pharmaceutical technology sector, utilizing AI-driven platforms for molecular discovery and early-stage drug development.